Michael Perry joins Avita Medical board
Avita Medical Ltd. (ASX:AVH; OTCQX:AVMXY) has appointed Dr. Michael Perry to its board. Dr. Perry is VP and senior global program head, Stem Cell Therapy, at Novartis Pharmaceuticals, and has over 25 years of pharmaceutical/biotech management and development experience.
“Michael brings a wealth of experience and scientific acumen as well as the insights that come from running successful large global divisions and emerging start-ups,” Avita CEO Dr. William Dolphin said in a statement. “Michael will be a great addition to our board and I am delighted to be working with him.”
Dr. Perry said Avita has the potential to make a significant impact in the field of regenerative medicine. “I look forward to sharing my experiences and contributing to the future direction and growth at this early stage in the company’s history.”